- Home
- YXT vs RAPT Comparison
YXT vs RAPT Comparison
Compare YXT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- RAPT
- Stock Information
- Founded
- YXT 2011
- RAPT 2015
- Country
- YXT China
- RAPT United States
- Employees
- YXT N/A
- RAPT N/A
- Industry
- YXT
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- RAPT Health Care
- Exchange
- YXT NYSE
- RAPT Nasdaq
- Market Cap
- YXT 102.1M
- RAPT 117.5M
- IPO Year
- YXT 2024
- RAPT 2019
- Fundamental
- Price
- YXT $0.87
- RAPT $0.75
- Analyst Decision
- YXT
- RAPT Hold
- Analyst Count
- YXT 0
- RAPT 7
- Target Price
- YXT N/A
- RAPT $5.00
- AVG Volume (30 Days)
- YXT 199.9K
- RAPT 821.6K
- Earning Date
- YXT 05-21-2025
- RAPT 05-08-2025
- Dividend Yield
- YXT N/A
- RAPT N/A
- EPS Growth
- YXT N/A
- RAPT N/A
- EPS
- YXT N/A
- RAPT N/A
- Revenue
- YXT $45,374,087.00
- RAPT N/A
- Revenue This Year
- YXT N/A
- RAPT N/A
- Revenue Next Year
- YXT N/A
- RAPT N/A
- P/E Ratio
- YXT $1.22
- RAPT N/A
- Revenue Growth
- YXT N/A
- RAPT N/A
- 52 Week Low
- YXT $0.47
- RAPT $0.75
- 52 Week High
- YXT $11.00
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- RAPT 38.29
- Support Level
- YXT N/A
- RAPT $0.75
- Resistance Level
- YXT N/A
- RAPT $0.88
- Average True Range (ATR)
- YXT 0.00
- RAPT 0.09
- MACD
- YXT 0.00
- RAPT 0.00
- Stochastic Oscillator
- YXT 0.00
- RAPT 5.04
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.